Bliss Gvs Pharma Ltd. (BSE: 506197) is a Mumbai, Maharashtra-based company in the Non-Prescription Drugs industry. With a market capitalisation of ₹6,817 Cr, it ranks #725 by market cap among the 6,197 Indian listed companies on FinBizNet, and #3 of 9 in Non-Prescription Drugs. At ₹673.60 (as of 16 Nov 2026), the share price is 9.0% below its 52-week high of ₹739.90 and 426.7% above its 52-week low of ₹127.90. The share price is up 426.3% over one year and up 31.0% over three months.
| Current Price | ₹673.60 |
|---|---|
| Market Cap | ₹6,817 Cr |
| BSE Code | 506197 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Non-Prescription Drugs |
| P/E Ratio | 53.9 |
| Return on Equity | 11.60% |
| Return on Assets | 5.87% |
| 52-Week Range | ₹127.90 – ₹739.90 |
| 1-Year Price Change | +426.3% |
| 3-Month Price Change | +31.0% |
| Beta (1Y) | 0.94 |
| Dividend Yield | 0.31% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.blissgvs.com |
| Revenue | ₹313 Cr |
|---|---|
| Net Profit | ₹53 Cr |
| Net Margin | 17.0% |
| EPS (Basic) | ₹4.92 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Bliss Gvs Pharma Ltd. reported revenue of ₹313 Cr in Q2 FY27, up 28.2% from ₹244 Cr in Q2 FY26 and up 9.7% from ₹286 Cr in Q1 FY27. It posted a net profit of ₹53 Cr for the quarter, against a net profit of ₹29 Cr in Q2 FY26 (up 86.6%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹198 Cr (Q4 FY25) to ₹313 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹313 Cr | ₹53 Cr | 17.0% |
| Q1 FY27 | ₹286 Cr | ₹51 Cr | 18.0% |
| Q4 FY26 | ₹257 Cr | ₹37 Cr | 14.4% |
| Q3 FY26 | ₹218 Cr | ₹25 Cr | 11.4% |
| Q2 FY26 | ₹244 Cr | ₹29 Cr | 11.7% |
| Q1 FY26 | ₹207 Cr | ₹44 Cr | 21.4% |
| Q4 FY25 | ₹198 Cr | ₹17 Cr | 8.4% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 50.07% of Bliss Gvs Pharma Ltd.'s shares as of Sept 2026, against 35.39% in Sept 2025 (+14.68 percentage points). Delivery averaged 100.0% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotion, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provides other healthcare products, such as balms, nasal inhalers, over-the-counter products, petroleum jellies, roll-ons, shampoo, soaps, sprays, and vaginal washes. In addition, it offers therapeutic products consisting of analgesics, antacids, anxiolytics, and haematinics; anti-bacterials, antibiotics, anti-diabetics, anti-diarrheals, anti-emetics, antifungals, anti-haemorrhoidals, anti-helmintics, anti-infectives, anti-inflammatories, anti-malarials
1. Pharmaceutical and Healthcare-This segment develops, manufactures, and markets pharmaceutical formulations. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. 2. Segment Adjustment-0 3. Health Care-This segment offers health care products. 4. Corporate-0
1. Pharmaceutical and Healthcare-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Glaxosmithkline Pharmaceuticals Ltd. | ₹44,982 Cr | 43.4 | 48.91% | ₹1,184 Cr | +3.3% |
| Alembic Pharmaceuticals Limited (Aplltd) | ₹20,245 Cr | 30.5 | 12.36% | ₹2,603 Cr | +11.7% |
| Bliss Gvs Pharma Ltd. | ₹6,817 Cr | 53.9 | 11.60% | ₹313 Cr | +426.3% |
| Zota Health Care Ltd | ₹4,585 Cr | n/m | -16.05% | ₹199 Cr | -15.1% |
| Amrutanjan Health Care Ltd. | ₹1,467 Cr | 25.3 | 16.62% | ₹135 Cr | -28.1% |
| Jenburkt Pharmaceuticals Ltd. | ₹433 Cr | 12.5 | 18.84% | — | -11.8% |
| Sat Kartar Life Limited | ₹256 Cr | 15.7 | 25.30% | — | — |
| Vista Pharmaceuticals Ltd. | ₹40 Cr | n/m | -10.82% | — | -37.1% |
| Welcure Drugs & Pharmaceuticals | ₹23 Cr | n/m | -5.50% | — | -64.2% |
Listed by market capitalisation. Ratios are shown for context only.
Bliss Gvs Pharma Ltd. is trading at ₹673.60, with a market capitalisation of ₹6,817 Cr.
Bliss Gvs Pharma Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Non-Prescription Drugs).
Bliss Gvs Pharma Ltd. has a P/E of 53.9 and a return on equity of 11.60%.
Bliss Gvs Pharma Ltd. is listed on the BSE under the scrip code 506197.
Bliss Gvs Pharma Ltd.'s share price is up 426.3% over one year and up 31.0% over three months. Its 52-week range is ₹127.90 to ₹739.90.
In Q2 FY27, Bliss Gvs Pharma Ltd. reported revenue of ₹313 Cr and net profit of ₹53 Cr, with basic EPS of ₹4.92 (consolidated, parsed from the company's exchange filing).
Bliss Gvs Pharma Ltd. reported revenue of ₹313 Cr in Q2 FY27, up 28.2% from ₹244 Cr in Q2 FY26 and up 9.7% from ₹286 Cr in Q1 FY27.
Promoters held 50.07% of Bliss Gvs Pharma Ltd.'s shares as of Sept 2026, against 35.39% in Sept 2025 (+14.68 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.